| Warner Mountain Indian Health Project | |
|
132 Mee Thee Uh Road Fort Bidwell CA 96112 | |
| (530) 279-6194 | |
| (530) 279-6288 |
| Full Name | Warner Mountain Indian Health Project |
|---|---|
| Speciality | Clinic/Center |
| Location | 132 Mee Thee Uh Road, Fort Bidwell, California |
| Authorized Official Name and Position | Candice Dawn Russell (CLINIC MANAGER) |
| Authorized Official Contact | 5302796194 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Warner Mountain Indian Health Project Po Box 247 Fort Bidwell CA 96112-0247 Ph: (530) 279-6194 | Warner Mountain Indian Health Project 132 Mee Thee Uh Road Fort Bidwell CA 96112 Ph: (530) 279-6194 |
| NPI Number | 1093931107 |
|---|---|
| Provider Enumeration Date | 04/17/2007 |
| Last Update Date | 07/02/2008 |
| Medicare PECOS PAC ID | 5890960355 |
|---|---|
| Medicare Enrollment ID | O20111212000333 |
News Archive
Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML).
According to the World Health Organization, cardiovascular diseases remain the leading cause of death worldwide. At the same time, 80 out of 100 cases of stroke can be prevented. The number of people suffering from various diseases of the musculoskeletal system is also steadily growing every year.
A new study by biomedical engineering researchers at the University of Arkansas could significantly improve methods for detecting and diagnosing congenital heart disease in infants and small children.
Helsinn Healthcare S.A. and Eisai Inc. today announce the signing of a licensing agreement granting Eisai Inc. commercialization rights for a new product for potential use in the prevention of chemotherapy-induced nausea and vomiting in the United States.
The Washington Post: "The Department of Veterans Affairs is preparing for more than 150,000 Vietnam War veterans to apply for benefits in the next 18 months thanks to new regulations making it easier to compensate for health problems caused by exposure to the Vietnam-era defoliant Agent Orange. Changes set for publication in Tuesday's Federal Register could result in payouts of about $42 billion in the next decade, VA said.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093931107 | NPI | - | NPPES |
| THP70973F | Medicaid | CA | |
| O5D0692143 | Other | CA | CLIA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QR1300X | Clinic/center - Rural Health | (* (Not Available)) | Primary |
| Provider Name | Donna Schindler |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1235203597 PECOS PAC ID: 2961393426 Enrollment ID: I20170525001195 |
News Archive
Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML).
According to the World Health Organization, cardiovascular diseases remain the leading cause of death worldwide. At the same time, 80 out of 100 cases of stroke can be prevented. The number of people suffering from various diseases of the musculoskeletal system is also steadily growing every year.
A new study by biomedical engineering researchers at the University of Arkansas could significantly improve methods for detecting and diagnosing congenital heart disease in infants and small children.
Helsinn Healthcare S.A. and Eisai Inc. today announce the signing of a licensing agreement granting Eisai Inc. commercialization rights for a new product for potential use in the prevention of chemotherapy-induced nausea and vomiting in the United States.
The Washington Post: "The Department of Veterans Affairs is preparing for more than 150,000 Vietnam War veterans to apply for benefits in the next 18 months thanks to new regulations making it easier to compensate for health problems caused by exposure to the Vietnam-era defoliant Agent Orange. Changes set for publication in Tuesday's Federal Register could result in payouts of about $42 billion in the next decade, VA said.
› Verified 4 days ago
| Provider Name | Danielle Anne Eigner |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1801989280 PECOS PAC ID: 9133290539 Enrollment ID: I20180423000031 |
News Archive
Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML).
According to the World Health Organization, cardiovascular diseases remain the leading cause of death worldwide. At the same time, 80 out of 100 cases of stroke can be prevented. The number of people suffering from various diseases of the musculoskeletal system is also steadily growing every year.
A new study by biomedical engineering researchers at the University of Arkansas could significantly improve methods for detecting and diagnosing congenital heart disease in infants and small children.
Helsinn Healthcare S.A. and Eisai Inc. today announce the signing of a licensing agreement granting Eisai Inc. commercialization rights for a new product for potential use in the prevention of chemotherapy-induced nausea and vomiting in the United States.
The Washington Post: "The Department of Veterans Affairs is preparing for more than 150,000 Vietnam War veterans to apply for benefits in the next 18 months thanks to new regulations making it easier to compensate for health problems caused by exposure to the Vietnam-era defoliant Agent Orange. Changes set for publication in Tuesday's Federal Register could result in payouts of about $42 billion in the next decade, VA said.
› Verified 4 days ago
| Provider Name | Constance A Collins |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1477600195 PECOS PAC ID: 9739288515 Enrollment ID: I20180522000198 |
News Archive
Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML).
According to the World Health Organization, cardiovascular diseases remain the leading cause of death worldwide. At the same time, 80 out of 100 cases of stroke can be prevented. The number of people suffering from various diseases of the musculoskeletal system is also steadily growing every year.
A new study by biomedical engineering researchers at the University of Arkansas could significantly improve methods for detecting and diagnosing congenital heart disease in infants and small children.
Helsinn Healthcare S.A. and Eisai Inc. today announce the signing of a licensing agreement granting Eisai Inc. commercialization rights for a new product for potential use in the prevention of chemotherapy-induced nausea and vomiting in the United States.
The Washington Post: "The Department of Veterans Affairs is preparing for more than 150,000 Vietnam War veterans to apply for benefits in the next 18 months thanks to new regulations making it easier to compensate for health problems caused by exposure to the Vietnam-era defoliant Agent Orange. Changes set for publication in Tuesday's Federal Register could result in payouts of about $42 billion in the next decade, VA said.
› Verified 4 days ago
| Provider Name | Divya Krishnamoorthy |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1194742825 PECOS PAC ID: 9830192871 Enrollment ID: I20180522000365 |
News Archive
Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML).
According to the World Health Organization, cardiovascular diseases remain the leading cause of death worldwide. At the same time, 80 out of 100 cases of stroke can be prevented. The number of people suffering from various diseases of the musculoskeletal system is also steadily growing every year.
A new study by biomedical engineering researchers at the University of Arkansas could significantly improve methods for detecting and diagnosing congenital heart disease in infants and small children.
Helsinn Healthcare S.A. and Eisai Inc. today announce the signing of a licensing agreement granting Eisai Inc. commercialization rights for a new product for potential use in the prevention of chemotherapy-induced nausea and vomiting in the United States.
The Washington Post: "The Department of Veterans Affairs is preparing for more than 150,000 Vietnam War veterans to apply for benefits in the next 18 months thanks to new regulations making it easier to compensate for health problems caused by exposure to the Vietnam-era defoliant Agent Orange. Changes set for publication in Tuesday's Federal Register could result in payouts of about $42 billion in the next decade, VA said.
› Verified 4 days ago
| Provider Name | Robert D Frey |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1912934779 PECOS PAC ID: 0345250619 Enrollment ID: I20180522000757 |
News Archive
Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML).
According to the World Health Organization, cardiovascular diseases remain the leading cause of death worldwide. At the same time, 80 out of 100 cases of stroke can be prevented. The number of people suffering from various diseases of the musculoskeletal system is also steadily growing every year.
A new study by biomedical engineering researchers at the University of Arkansas could significantly improve methods for detecting and diagnosing congenital heart disease in infants and small children.
Helsinn Healthcare S.A. and Eisai Inc. today announce the signing of a licensing agreement granting Eisai Inc. commercialization rights for a new product for potential use in the prevention of chemotherapy-induced nausea and vomiting in the United States.
The Washington Post: "The Department of Veterans Affairs is preparing for more than 150,000 Vietnam War veterans to apply for benefits in the next 18 months thanks to new regulations making it easier to compensate for health problems caused by exposure to the Vietnam-era defoliant Agent Orange. Changes set for publication in Tuesday's Federal Register could result in payouts of about $42 billion in the next decade, VA said.
› Verified 4 days ago
| Provider Name | Gary Haffner |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1407950710 PECOS PAC ID: 3476551565 Enrollment ID: I20181129000705 |
News Archive
Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML).
According to the World Health Organization, cardiovascular diseases remain the leading cause of death worldwide. At the same time, 80 out of 100 cases of stroke can be prevented. The number of people suffering from various diseases of the musculoskeletal system is also steadily growing every year.
A new study by biomedical engineering researchers at the University of Arkansas could significantly improve methods for detecting and diagnosing congenital heart disease in infants and small children.
Helsinn Healthcare S.A. and Eisai Inc. today announce the signing of a licensing agreement granting Eisai Inc. commercialization rights for a new product for potential use in the prevention of chemotherapy-induced nausea and vomiting in the United States.
The Washington Post: "The Department of Veterans Affairs is preparing for more than 150,000 Vietnam War veterans to apply for benefits in the next 18 months thanks to new regulations making it easier to compensate for health problems caused by exposure to the Vietnam-era defoliant Agent Orange. Changes set for publication in Tuesday's Federal Register could result in payouts of about $42 billion in the next decade, VA said.
› Verified 4 days ago
| Provider Name | Patricia Chico |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1801162565 PECOS PAC ID: 2567782808 Enrollment ID: I20231227000178 |
News Archive
Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML).
According to the World Health Organization, cardiovascular diseases remain the leading cause of death worldwide. At the same time, 80 out of 100 cases of stroke can be prevented. The number of people suffering from various diseases of the musculoskeletal system is also steadily growing every year.
A new study by biomedical engineering researchers at the University of Arkansas could significantly improve methods for detecting and diagnosing congenital heart disease in infants and small children.
Helsinn Healthcare S.A. and Eisai Inc. today announce the signing of a licensing agreement granting Eisai Inc. commercialization rights for a new product for potential use in the prevention of chemotherapy-induced nausea and vomiting in the United States.
The Washington Post: "The Department of Veterans Affairs is preparing for more than 150,000 Vietnam War veterans to apply for benefits in the next 18 months thanks to new regulations making it easier to compensate for health problems caused by exposure to the Vietnam-era defoliant Agent Orange. Changes set for publication in Tuesday's Federal Register could result in payouts of about $42 billion in the next decade, VA said.
› Verified 4 days ago
News Archive
Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML).
According to the World Health Organization, cardiovascular diseases remain the leading cause of death worldwide. At the same time, 80 out of 100 cases of stroke can be prevented. The number of people suffering from various diseases of the musculoskeletal system is also steadily growing every year.
A new study by biomedical engineering researchers at the University of Arkansas could significantly improve methods for detecting and diagnosing congenital heart disease in infants and small children.
Helsinn Healthcare S.A. and Eisai Inc. today announce the signing of a licensing agreement granting Eisai Inc. commercialization rights for a new product for potential use in the prevention of chemotherapy-induced nausea and vomiting in the United States.
The Washington Post: "The Department of Veterans Affairs is preparing for more than 150,000 Vietnam War veterans to apply for benefits in the next 18 months thanks to new regulations making it easier to compensate for health problems caused by exposure to the Vietnam-era defoliant Agent Orange. Changes set for publication in Tuesday's Federal Register could result in payouts of about $42 billion in the next decade, VA said.
› Verified 4 days ago